Apr 1 2010
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that
patent infringement litigation pertaining to Teva's generic version of
sanofi-aventis and Debiopharm's Eloxatin (oxaliplatin injection) has
been dismissed by the United States District Court for the District of
New Jersey pursuant to a settlement between the parties.
The settlement, which provides for a full release of Teva, includes an
injunction prohibiting Teva from selling its oxaliplatin injection
product and a license to reenter the market at a later point in time.
Teva anticipates continued sales of its oxaliplatin injection at least
through June 30, 2010, and will resume shipping additional units August
9, 2012, subject to acceleration under certain contingencies.
Source:
Teva Pharmaceutical Industries Ltd.,
Healthy lifestyle choices can offset genetic risk for brain diseases